MAPT and Alzheimer disease: Emerging therapeutic approaches targeting Aβ and tau proteins themselves are failed at showing ideal efficacy in mitigating cognitive dysfunction in AD patients due to multifactorial influences (Nixon and Yang, 2011; Zeng et al., 2019).